By Chris Wack
X4 Pharmaceuticals said that the Food and Drug Administration approved Xolremdi capsules for use in patients 12 years of age and older with WHIM syndrome to increase the number...
Related Keywords
Chris Wack , Drug Administration , Breakthrough Therapy Designation , New Drug Application , Priority Review , Rare Pediatric Disease Priority Review Voucher , Dow Jones ,
comparemela.com © 2020. All Rights Reserved.